Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Account Payables (2016 - 2025)

Corcept Therapeutics' Change in Account Payables history spans 10 years, with the latest figure at $6.0 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 293.11% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $25.1 million, up 1340.99%, while the annual FY2025 figure was $25.1 million, 1340.99% up from the prior year.
  • Change in Account Payables for Q4 2025 was $6.0 million at Corcept Therapeutics, down from $10.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $12.9 million in Q1 2025 and bottomed at -$4.9 million in Q1 2024.
  • The 5-year median for Change in Account Payables is $99500.0 (2021), against an average of $1.5 million.
  • The largest annual shift saw Change in Account Payables crashed 1110.27% in 2021 before it surged 5303.03% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $364000.0 in 2021, then skyrocketed by 1065.38% to $4.2 million in 2022, then tumbled by 84.98% to $637000.0 in 2023, then tumbled by 587.6% to -$3.1 million in 2024, then soared by 293.11% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Change in Account Payables are $6.0 million (Q4 2025), $10.9 million (Q3 2025), and -$4.8 million (Q2 2025).